Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors ...Middle East

Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer treatment for worldwide markets HEIDELBERG, Germany and SEOUL, South Korea, July 16, 2024...

Hence then, the article about full life technologies sk biopharmaceuticals enter licensing agreement for novel therapeutic targeting multiple solid tumors was published today ( Wednesday 17/07/2024 - 05:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors )

Also on site :

• Potato futures are soaring – should the world be worried?
• Starbucks to Cut 300 Jobs— Here's How to Handle a Layoff According to a Pro
• Elon Musk Doubles Down on Slamming ‘The Odyssey’ Casting: ‘Who Specifically Is the A–hole Who Added DEI Lies to Academy Awards Eligibility?’